Brief: NGM Bio Announces Oral And Late-Breaking Poster Presentations Supporting Its Myeloid Reprogramming Portfolio At Upcoming 2022 Aacr Annual Meeting
08/03/2022 23:07
March 8 (Reuters) - NGM Biopharmaceuticals Inc NGM.O :
* NGM BIO ANNOUNCES ORAL AND LATE-BREAKING POSTER
PRESENTATIONS
SUPPORTING ITS MYELOID REPROGRAMMING PORTFOLIO AT UPCOMING 2022
AACR ANNUAL MEETING
Source text for Eikon: ID:nGNX99Y7PN
Further company coverage: NGM.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on NGM Biopharmaceuticals
See all newsBrief: NGM Biopharmaceuticals Q4 Net Income USD -27.67 Million
Brief: NGM Bio Enters into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group
NGM Biopharmaceuticals Inc expected to post a loss of 39 cents a share - Earnings Preview
Brief: Ngm Biopharmaceuticals Says It Got Written Notice From Nasdaq Informing It Has Regained Compliance With Nasdaq Listing
Brief: NGM Bio Announces New Clinical Data From Ongoing Trial Of Ngm707 In Advanced Solid Tumors